Corvus Pharmaceuticals Says Phase 1/1b Soquelitinib T Cell Lymphoma Data Published In Blood Showed Objective Responses In 9 Of 24 Patients, Median Overall Survival Of 28.1 Months

Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) Estimate

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 90 percent decrease over losses of $(0.10) per share from the

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?

Corvus Pharmaceuticals director David Scott Moore purchased 21,700 common shares for approximately $250,000 on June 11, 2026, marking his first investment in the company since joining as a director in October. Moore also received 15,000 stock options vesting in a year. The insider buy is viewed as a positive signal, though it should be considered alongside other investment factors.

Corvus Pharma Participates In New $13.5M Financing For Angel Pharmaceuticals